Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
暂无分享,去创建一个
A. Nademanee | P. Stiff | V. Bachanova | T. Masszi | J. Walewski | J. Sweetenham | A. Gianni | A. Carella | C. Moskowitz | M. Abidi | A. Sureda | D. Huebner | E. Sievers | Andy Chi | J. Hołowiecki | E. Agura | N. Hunder | A. Chen | D. Osmanov | E. K. Larsen